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Quinidine therapy is one of the most common causes of
the acquired long QT syndrome and the morphologically
distinctive tachyarrhythmia torsade de pointes. Clinical
data from our institution and others have revealed a
number of characteristic features: quinidine plasma con-
centrations are generally low, marked QRS prolongation
is absent, hypokalemia is frequent and abrupt heart rate
slowing just before the initiation of a paroxysm is almost
invariable. The lack of correlation between plasma quin-
idine concentrations and this adverse drug effect raises
the possibility either that external factors (for example,
hypokalemia) modulate the response to quinidine in vivo
or that one or more unmeasured active metabolites play
a role.
Therefore, the effects of alterations in extracellular
potassium and stimulation rate on the electrophysiologic
effects of quinidine were examined in canine Purkinje
fibers. It was found that a form of triggered automat-
icity, early afterdepolarizations, is reliably produced in
the presence of quinidine when extracellular potassium
It has been recognized since the 1920s that up to 5 to 10%
of patients in whom quinidine therapy is initiated will de-
velop recurrent syncopal episodes, and occasionally die,
within the first several days of treatment. Although "quin-
idine syncope" was initially attributed to the vasodilator
properties of the drug, it was recognized in 1964 (1) that
in fact a distinctive ventricular tachyarrhythmia was the
cause. In 1966, Dessertenne (2) described a similar tachy-
cardia, in association with marked QT prolongation, in an
elderly patient with recurrent bradyarrhythmias. He coined
the term "torsade de pointes" which has since been applied
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is lowered and the stimulation rate is slowed. More re-
cently, the effects of a number of quinidine metabolites,
as well as the commonly found impurity dihydroquini-
dine, were characterized in canine Purkinje fibers in a
similar fashion. Although quinidine was the most potent
of the substances tested, both dihydroquinidine and 3-
hydroxyquinidine prolonged action potential and produced
early afterdepolarizations as did quinidine at long cycle
lengths.
Quinidine-induced torsade de pointes is a potentially
lethal adverse drug effect, occurring in 1 to 3% of pa-
tients. Hypokalemia and slow heart rates are commonly
observed in a clinical setting and, in the tissue bath,
quinidine and several of its metabolites induce abnormal
automatic behavior when extracellular potassium is low-
ered and stimulation rate is slowed. It is concluded that
early afterdepolarizations, a form of triggered auto-
maticity, may be responsible for induction of quinidine-
induced arrhythmias in humans.
(} Am Coil CardioI1986;8:73A-78A)
to all polymorphic ventricular tachycardias occurring in the
setting of marked QT interval prolongation. Polymorphic
ventricular tachycardia can of course occur in the absence
of QT prolongation and quinidine-like drugs may be effec-
tive in such cases; it is probably not appropriate to use the
term torsade de pointes in such patients (3).
When Dessertenne described his index case, he specu-
lated that the unusual configuration was due to ventricular
activation by at least two automatic foci at slightly different
rates. Indeed, this configuration can be replicated in this
fashion in animal models (4). Clinical electrophysiologic
studies have shown that premature stimulation can elicit
polymorphic ventricular tachycardia in some patients re-
ceiving quinidine (5). Although marked QT prolongation
was not seen in these studies, this initiation sequence never-
theless raised the possibility that reentrant mechanisms were
involved. Recently, it has been shown (6) that rapid ven-
tricular pacing after administration of fairly large doses of
quinidine intravenously can induce ventricular tachycardia
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in a minority of dogs with coronary occlusion and on car-
diopulmonary bypass; mapping studies in this model sug-
gested that multiple automatic foci were implicated.
However, several lines of evidence now suggest that
quinidine-induced torsade de pointes is not related to en-
hanced normal automaticity or reentry, but represents a clin-
ical example of triggered activity. Digitalis intoxication in
vitro represents the most widely studied example of trig-
gered activity. Digitalis produces afterdepolarizations that
increase in amplitude as stimulation rates increase and, with
sufficiently rapid stimulation rates, can reach threshold and
initiate spontaneous action potentials. In contrast to this
tachycardia-dependent triggered arrhythmia, available evi-
dence now implicates bradycardia-dependent triggered ac-
tivity as the initiating mechanism of quinidine-induced tor-
sade de pointes.
Clinical Studies
Incidence and initiation. Since the late 1970s, several
series of patients who developed torsade de pointes under
a variety of clinical circumstances have been described (7,8).
The common clinical features include marked QT prolon-
gation, a relatively high incidence of hypokalemia or hy-
pomagnesemia, or both, relative inefficacy of standard an-
titachycardia drugs and the efficacy of maneuvers to increase
heart rate (isoproterenol infusion or cardiac pacing). We
have had the opportunity to review our experience with a
large series of patients (24 patients) with this entity at our
institution (9). On the basis of nonreferral patients only, we
estimated that 2 to 3% of patients starting quinidine therapy
will develop this potentially lethal ventricular tachyarrhyth-
mia. Approximately one-half of quinidine concentrations
were below 2 JLg/ml, the lower limit of the usual therapeutic
range, and most serum potassium concentrations in our se-
ries were below 4 mEq/liter, usually in association with
diuretic therapy. QT intervals were markedly prolonged (by
definition) whereas QRS intervals were prolonged only
slightly, again emphasizing the fact that this reaction is not
a result of poisoning by high concentrations of quinidine.
Figure 1. Electrocardiogram of a typical paroxysm of quinidine-
induced torsade de pointes demonstrating the typical cycle length
changes just before an episode. The tachycardia starts (light ar-
row) after the apex of the T wave (heavy arrow). In the vast
majority of instances of quinidine-induced torsade de pointes, the
"initiating cycle" is markedly prolonged and is longer than the
"preinitiating cycle. "
7~
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Examination of the initiation of the paroxysms revealed a
strikingly stereotypic pattern of cycle length changes (Fig.
1). The cardiac cycle immediately preceding the last sinus
beat before the episode was inevitably longer than the cycle
it followed, most commonly as a result of a postectopic or
posttachycardia pause. The QT interval of the sinus beat
terminating this long cycle was markedly prolonged and the
arrhythmia began on or just after the peak of the T wave
of this QT interval. This phenomenon has been described
in a number of different fashions (7,10), the central obser-
vation being that heart rate appears to slow abruptly just
before the initiation of the arrhythmia.
Contributing factors. Of the 24 cases at Vanderbilt, 20
occurred within the first 5 days of therapy, but in 4, torsade
de pointes occurred during long-term quinidine therapy. In
three of these, the episode was clearly associated with the
development of the hypokalemia, whereas in a fourth, heart
block appeared to be the initiating factor. Some potentially
associated clinical factor (most commonly bradyarrhythmia
or hypokalemia) could be associated with the development
of torsade de pointes in 20 of the 24 patients. These clinical
data raised several hypotheses that we have begun to test.
First, it is possible that this "idiosyncratic" drug reaction
actually represents a predictable effect of quinidine when
external circumstances are modified (for example, by hy-
pokalemia). Alternatively, the failure of the quinidine con-
centrations to be closely associated with the development
of this adverse drug effect raises the possibility that one or
more unmeasured metabolites may contribute in part to the
variable response.
In Vitro Studies
In these studies, action potentials from Purkinje fibers in
free-running canine false tendons from either ventricle were
studied (11). They were perfused with standard Tyrode's
solution and bubbled with a mixture of 95% oxygen and
5% carbon dioxide. Extracellular potassium (Ke) varied from
2.7 to 5 mM as described later. Preparations were driven
by field stimulation at a wide range of cycle lengths (from
300 to 8,000 ms) and action potentials as well as the max-
imal upstroke slope of phase 0 CV-max) were photographed
from an oscilloscope. In each experiment, baseline mea-
surements were made first, and then the fiber was exposed
to the drug.
Quinidine, action potential and afterdepolarizations.
The initial studies focused on the effects of a range of
concentrations of quinidine (0.1 to 10 jLM). After a 30
minute exposure to 0.1 jLM quinidine, no action potential
characteristic was altered at any cycle length. However,
after a 30 minute exposure to 1 jLM quinidine (0.3 JLglml,
a low concentration), action potential was markedly pro-
longed at long cycle lengths. At 10 jLM quinidine, action
potential was prolonged still further, particularly at long
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cycle lengths, whereas Vmax depression became evident.
As has been repeatedly described for sodium channel block-
ing antiarrhythmic drugs, Vmax depression was most evi-
dent at rapid stimulation rates. Because action potential
prolongation was seen at slow rather than rapid rates of
stimulation and at lower concentrations of quinidine than
those depressing Vmax, and because selective sodium chan-
nel blockade (by tetrodotoxin) l;hortenl; action potentia]!:, it
seems likely that action potential prolongation is mediated
by some nonsodium blocking action of quinidine, perhaps
its interference with the time-dependent outward potassium
current, ix (12). Lowering Ko in these experiments also
prolonged action potential duration, but in a cycle length-
independent fashion. Hence, as illustrated in Figure 2, low-
ering Ko in the presence of quinidine further prolonged
action potential at slow rates of stimulation.
In this setting, ajterdepolarizations arising in phase 3 of
the action potential (that is, before complete repolarization)
were consistently observed (Fig. 3). Although only 1 of 25
preparations displayed such early afterdepolarizations in the
absence of drug at cycle lengths greater than 4,000 ms, 50%
of preparations demonstrated early afterdepolarizations un-
der these conditions when exposed to 1 p.,M quinidine, and
the proportion rose to 78% with 10 p.M. Afterdepolariza-
tions were, by definition, only seen in the repolarization
phase of a preceding normal depolarization (hence the term
"triggered"). It has been suggested (13) that, in fact, only
the first of a train of such "afterdepolarizations" is trig-
gered, and that subsequent beats merely represent depolar-
Figure 2. Relation between cycle length and action potential du-
ration measured at 90% repolarization (APD90) in canine Purkinje
fibers. Quinidine (solid lines) increased the slope of the relation,
whereas lowering potassium (I(,,) in the presence or absence of
quinidine produced a leftward shift of the relation without changing
the slope.
ization-related automaticity (due either to depressed fast
inwiifd :'Iodium chnnneh Dr tD the L:akium L:hanneI).
Interventions to abolish afterdepolarizations: Tole of
action potential shortening. A number of interventions
were identified that abolished these early afterdepolariza-
tions. Decreasing basic cycle lengths to 1,000 to 2,000 ms
or less always abolished this form of triggered activity.
Raising Ko from 2.7 to 5 roM similarly abolished early
afterdepolarizations. Sodium channel blockade by low con-
centrations of tetrodotoxin (0.1 to 1.0 p.,M) or lidocaine (10
p.,M) was similarly effective. More recently, we have also
demonstrated that mexiletine (10 p.,M) produces the same
effect (14). The common denominator to all these inter-
ventions appears to be action potential shortening. It is not
warranted, on the basis of these data, to implicate a de-
pressed inward sodium current in the genesis of early af-
terdepolarizations, particularly as calcium channel blockade
may also prevent early afterdepolarizations (15).
Role of quinidine metabolites. We have also evaluated
the effects of a number of quinidine metabolites, as well as
the effects of the commonly found impurity dihydroquini-
dine, in this setting (16). These experiments were conducted
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Figure 3. Action potential changes induced by abruptly increasing
cycle length from 1,000 to 8,000 ms in the presence of quinidine
(10 /-LM) and low Ko (2.7 mM). This recording was made from
an oscilloscope screen with the camera shutter held open to record
successive action potentials. The last of a train of action potentials
at a cycle length of 1,000 ms produced the shortest action potential.
The first action potential at a cycle length of 8,000 ms was mark-
edly prolonged; the second was associated with a single early
afterdepolarization and the third with two early afterdepolariza-
tions.
with a Ko of 4 mM and drug concentrations of 10 p.M. We
found that none of the substances tested were more potent
than quinidine, but that both 3-0H quinidine, quinidine's
major metabolite, and dihydroquinidine were approximately
equally potent to quinidine in depressing Ymax at rapid
rates of stimulation and prolonging action potential at slow
rates of stimulation. Early afterdepolarizations were seen at
slow rates of stimulation in the presence of quinidine (4 of
10 experiments), 3-0H quinidine (3 of 8) and dihydroquin-
idine (5 of 9).
Linking in Vitro and Clinical Studies
The parallels between this form of triggered activity in
vitro and the clinical data are striking. Each can occur at
low quinidine concentrations (which are insufficient to sub-
stantially alter indexes of sodium channel function, that is,
Ymax or QRS duration). Marked prolongation of repolar-
ization when stimulation rate is slowed and arrhythmia ini-
tiation late in the repolarization process are common to both
situations. Decreases in extracellular potassium facilitate
these arrhythmias and raising Ko or increasing stimulation
rate, or both, reverses both the clinical and in vitro abnor-
mality.
Bradycardia-dependent early afterdepolarizations. A
number of other interventions similarly cause bradycardia-
dependent early afterdepolarizations in vitro and arrhyth-
mias in vivo. Cesium, a blocker of potassium conductances,
consistently triggers early afterdepolarizations in canine
Purkinje fibers and, when injected intravenously in dogs,
can produce an arrhythmia that has all the clinical features
of torsade de pointes (17). More commonly, the rhythm is
monomorphic but, like torsade de pointes, its development
is facilitated by an abrupt slowing in heart rate. Calcium
channel blockade by D600 (15) or sodium channel blockade
by tetrodotoxin (17) prevents the arrhythmia. Acidosis has
also been known to cause early afterdepolarizations in ca-
nine Purkinje fibers (18). Computer reconstruction of action
potentials in these experiments suggested that the inward
sodium current during plateau (the "window current") played
a primary role (19).
Role of NAPA. N-acetylprocainamide (NAPA), the ma-
jor metabolite of procainamide, has been shown to prolong
action potential in canine Purkinje fibers and ventricular
muscle (20). However, unlike procainamide, it exerts little
or no effect on Ymax or on His-Purkinje system conduction
velocity. Canine Purkinje fibers exposed to NAPA and driven
at slow stimulation rates demonstrated early afterdepolari-
zations, and when NAPA was injected intravenously in dogs
with a slow heart rate, arrhythmias were frequently seen
(20). Again, monomorphic arrhythmias occurred more com-
monly than polymorphic arrhythmias. In a Purkinje fiber-
ventricular muscle preparation, excitation of muscle by a
NAPA-induced early afterdepolarization in Purkinje fiber
appeared to be a function of either the time or the potential
at which the early afterdepolarization arose (21), When af-
terdepolarizations arose late in phase 3 (that is, at long
coupling intervals to the previous upstroke and at fairly
negative membrane potentials), ventricular muscle devel-
oped an extrasystole. On the other hand, with early after-
depolarizations developing earlier during repolarization (that
is, with a shorter coupling interval and at a less negative
transmembrane potential), ventricular muscle frequently was
not excited.
, ~
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Figure 4. Recordings of monophasic action po-
tential (upper tracing) and electrocardiogram
(lower tracing) in an isolated rabbit heart per-
fused with quinidine and low extracellular mag-
nesium, calcium and potassium. There is AV
block and, with a slow stimulation rate, runs of
polymorphic triggered activity were observed.
Cycle length (CL) = 6,000 ms.
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Bradycardia-dependent triggered activity in the rab-
bit heart. We have attempted to link our clinical and in
vitro observations by examining the effects of quinidine in
an isolated rabbit heart preparation (22) that was perfused
with Tyrode's solution modified to contain low extracellular
magnesium (0.25 mM), low extracellular calcium (1.35 mM)
and low extracellular potassium (2.7 mM). To slow heart
rate, the atrioventricular (AV) node was destroyed by for-
malin injection. We defined bradycardia-dependent trig-
gered activity as more than one ventricular depolarization
in response to a single ventricular stimulus occurring when
the preparation was driven at a rate slower than some critical
rate. Exposure of hearts to 10 JLM of quinidine for 30 min-
utes resulted in bradycardia-dependent triggered activity in
10 of 19 experiments. In an additional 10 hearts not treated
with the drug, bradycardia-dependent triggered activity was
noted in 4. However, in quinidine-treated hearts, the critical
cycle length above which triggered activity occurred was
2,000 ms or less in 6 of 10 experiments, whereas in the
absence of quinidine, triggering, when it occurred, devel-
oped at critical cycle lengths above 2,000 ms. As in the
experiments with cesium and NAPA, the observed brady-
cardia-dependent triggered activity was usually monomor-
phic, although occasionally polymorphic activity was ob-
served (Fig. 4). Raising K., to 7 mM or increasing stimulation
rate abolished bradycardia-dependent triggered activity.
Preliminary studies in this model have shown that verapamil
also blocks bradycardia-dependent triggered activity in-
duced by quinidine. ~aising extracellular magnesium had
two effects: 1) bradycardia-dependent triggered activity was
no longer seen in the absence of quinidine, and 2) the critical
cycle lengths above which triggering was seen in the pres-
ence of quinidine were prolonged.
We have also recorded monophasic action potential sig-
nals from ventricular epicardium in hearts demonstrating
triggered activity. In this setting, defonnities of the tenninal
phase of repolarization were frequently seen; similar de-
fonnities have also been reported during attempts to record
monophasic action potential signals in patients with the con-
genital long QT syndrome and torsade de pointes (23).
Summary
These in vitro, ex vivo, in vivo and clinical studies sug-
gest that early afterdepolarizations may play a role at least
in initiating arrhythmias that are seen when cardiac repo-
larization is markedly prolonged. The simplest clinical sit-
uation in which studies have been feasible has been antiar-
rhythmic drug-induced QT prolongation and torsade de
pointes. Our clinical and in vitro findings suggest that quin-
idine, its metabolites and dihydroquinidine may all playa
role, but that external factors must modulate the response
in an individual patient. These include defined abnonnalities
such as hypokalemia or hypomagnesemia as well as other,
less well characterized factors such as autonomic tone (24)
or focal cardioneural disease (25). Other situations in which
prolongation of cardiac repolarization occurs and in which
potentially lethal ventricular tachyarrhythmias may develop
include the congenital long QT syndrome and acute (26)
and chronic (27) myocardial ischemia. Further clinical and
in vitro studies are required to establish the relative impor-
tance of this hitherto underemphasized mechanism of ar-
rhythmogenesis in clinical medicine.
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